Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET

Journal of Nuclear Medicine

Volumn 46, Issue 1, 2005, Pages 114-120

  Waldherr, Christian ^a   Mellinghoff, Ingo K ^a   Tran, Chris ^a   Halpern, Benjamin S ^a   Rozengurt, Nora ^a   Safaei, Arash ^a   Weber, Wolfgang A ^a   Stout, David ^a   Satyamurthy, Nagichettiar ^a   Barrio, Jorge ^a   Phelps, Michael E ^a   Silverman, Daniel H ^a   Sawyers, Charles L ^a   Czernin, Johannes ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FDG PET; 18F FLT PET; ErbB; Small molecule kinase inhibitor; Thymidine kinase

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CELL NUCLEUS ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TRACER; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INHIBITION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TUMOR CELL; XENOGRAFT; ANIMAL; CANCER INVASION; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; EVALUATION; METABOLISM; METHODOLOGY; MOUSE; MOUSE MUTANT; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 15044347137     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
3. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 2003;17:2998-3010.
4. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Anna Rev Med. 2002;53:89-112.
5. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657.
6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347: 472-480.
7. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-IS]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
8. Amer ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 1995;67:155-186.
9. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8: 3315-3323.
10. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52: 1602-1606.
11. 18F-3′-fluoro- 3′-deoxy-L-thymidine. Clin Cancer Res. 2004;10:1685-1690.
12. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
13. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687.
14. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
15. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027-2032.
16. 18F]FLT is a tumor PET marker that reflects ATP-dependent thymidine kinase 1 activity [abstract]. J Nucl Med. 2004;45(suppl):334P.
17. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-287.
18. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20:1S-13S.
19. 18F-fluoro-d- glucose. Mol Imaging Biol. 2002;4:65-70.
20. 18F]FLT preparation. J Radioanal Nucl Chem. 2002;251:55-58.
21. 18F]FLT). J Radioanal Nucl Chem. 2000;243:843-846.
22. Tai C, Chatziioannou A, Siegel S, et al. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol. 2001;46:1845-1862.
23. Mellinghoff IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbBl/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 2002;62:5254-5259.
24. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001; 410:37-40.
25. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest. 2003;111:1620-1629.
26. Scimeca JC, Ballotti R, Alengrin F, et al. Metabolic effects induced by epidermal growth factor (EOF) in cells expressing EOF receptor mutants. J Biol Chem. 1989;264:6831-6835.
27. Sistonen L, Holtta E, Lehvaslaiho H, Lehtola L, Alitalo K. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and omithine decarboxylase. J Cell Biol. 1989;109:1911-1919.
28. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
29. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling, Clin Cancer Res. 2003;9:4340-4346.
30. Lodish HF, Berk A, Zipursky S, Matsudaira P, Baltimore D, Darnell J. Molecular Cell Biology. 4th ed. New York, NY: WH Freeman: 2000.
31. 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31:169-178.
32. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med. 2004;45:519-525.
33. 18F-FLT for monitoring response to antiproliferative therapy in a mouse lymphoma xenotransplant model [abstract]. J Nucl Med. 2004;45(suppl):154P.
34. Nottebrock H, Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol. 1977;26:2175-2179.
35. 76Br-BFU as proliferation markers. J Nucl Med. 2002;43:1688-1698.
36. Mikulits W, Hengstschlager M, Sauer T, Wintersberger E, Mullner EW. Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity. J Biol Chem. 1996;271:853-860.
37. Schwanz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy- 3′fluorothy-midine uptake. Nucl Med Biol. 2004;31:419-423.
38. 18F]FLT PET for diagnosis and staging of thoracic tumours. Ear J Nucl Med Mol Imaging. 2003;30:1407-1412.
39. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931-4941.